More Than Meets the Kappa for Antibody Superantigen Protein L (PpL)

More Than Meets the Kappa for Antibody Superantigen Protein L (PpL)

Immunoglobulin superantigens play an important role in affinity purification of antibodies and the microbiota-immune axis at mucosal areas. Based on current understanding, <i>Staphylococcal</i> Protein A (SpA), <i>Streptococcal</i> Protein G (SpG) and <i>Finegoldia</...

Full description

Bibliographic Details
Main Authors:	Wei-Li Ling, Joshua Yi Yeo, Yuen-Ling Ng, Anil Wipat, Samuel Ken-En Gan
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Antibodies
Subjects:	Pertuzumab Trastuzumab IgG1 VH families VK families immunoglobulin
Online Access:	https://www.mdpi.com/2073-4468/11/1/14

Similar Items

Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients
by: Thomas Christensen, et al.
Published: (2020-06-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer
by: Michela Donadio
Published: (2018-06-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
by: Oğuzcan Kınıkoğlu, et al.
Published: (2024-06-01)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
by: Alexey A. Larionov
Published: (2018-04-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding
by: Wei-Li Ling, et al.
Published: (2018-03-01)

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
by: Azzurra Irelli, et al.
Published: (2024-01-01)

Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy
by: Sainan Cheng, et al.
Published: (2023-05-01)

Long-term survival in a young woman with recurrent HER2-positive breast cancer.
by: Gianluca Cotroneo
Published: (2018-06-01)

Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)
by: Tobias Berg, et al.
Published: (2020-12-01)

The Conundrum of Adjuvant HER2 Treatment Options
by: Ajaz Bulbul, et al.
Published: (2018-05-01)

The dispensability of VH-VL pairing and the indispensability of VL domain integrity in the IgG1 secretion process
by: Juho Choi, et al.
Published: (2024-05-01)

Case report: A promising neoadjuvant treatment option for individuals with locally advanced HER2-positive breast cancer involves the use of Pyrotinib Maleate in combination with Trastuzumab and Pertuzumab
by: Chi Pan, et al.
Published: (2024-07-01)

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
by: Dai Okemoto, et al.
Published: (2024-09-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
by: Xiaoyun Liu, et al.
Published: (2022-09-01)

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
by: Sandor Schokker, et al.
Published: (2020-01-01)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
by: Shengnan Yu, et al.
Published: (2017-11-01)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
by: Juliana Bentes Hughes, et al.
Published: (2012-06-01)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
by: Laure Thouvenin, et al.
Published: (2021-08-01)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
by: Luai S. Al Rabadi, et al.
Published: (2021-10-01)

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer
by: Maria Moritti, et al.
Published: (2018-06-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

Phylogenetic conservation of the 3’ cryptic recombination signal sequence (cRSS) in the VH genes of jawed vertebrates
by: Yi eSun, et al.
Published: (2012-12-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Single Domain Antibody Fragments as Drug Surrogates Targeting Protein–Protein Interactions inside Cells
by: Terence H. Rabbitts, et al.
Published: (2013-05-01)

Alterations of Total Serum Immunoglobulin Concentrations in Pemphigus and Pemphigoid: Selected IgG2 Deficiency in Bullous Pemphigoid
by: Stanislav Khil'chenko, et al.
Published: (2020-09-01)

Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights
by: Sharaf B, et al.
Published: (2025-03-01)

The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review
by: Luciana Castro Garcia Landeiro, et al.
Published: (2024-08-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
by: Abdulrazaq S. Al-Jazairi, et al.
Published: (2023-09-01)

Using quantitative single molecule localization microscopy to optimize multivalent HER2-targeting ligands
by: Devin L. Wakefield, et al.
Published: (2023-04-01)

Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba
by: Elías A. Gracia Medina, et al.
Published: (2023-01-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity
by: Xiaoyu Ding, et al.
Published: (2020-10-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)